RECRUITING

Gut Microbiome Studies in Patients with POEMS Syndrome and Other Plasma Cell Disorders

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders

Official Title

Gut Microbiome Studies in Patients with POEMS Syndrome and Other Plasma Cell Disorders

Quick Facts

Study Start:2021-12-29

Study Completion:2028-12-29

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06252948

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Diagnosed with POEMS syndrome (newly diagnosed or in remission) or with newly diagnosed multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), amyloid light chain (AL) amyloidosis or healthy controls from their households	* Age under 18 years * Pregnancy * Substance abuse * Antibiotics use or gastrointestinal endoscopy in the 3 months prior to the study participation * Chronic gastrointestinal disorder * Gastrointestinal surgeries in the past 2 years * Chemotherapy (including anti-plasma cell treatment and steroids) or radiation treatment for cancer within the last 2 years or active cancer (other than plasma cell disorder)

Inclusion Criteria

Exclusion Criteria

* Diagnosed with POEMS syndrome (newly diagnosed or in remission) or with newly diagnosed multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), amyloid light chain (AL) amyloidosis or healthy controls from their households

* Age under 18 years
* Pregnancy
* Substance abuse
* Antibiotics use or gastrointestinal endoscopy in the 3 months prior to the study participation
* Chronic gastrointestinal disorder
* Gastrointestinal surgeries in the past 2 years
* Chemotherapy (including anti-plasma cell treatment and steroids) or radiation treatment for cancer within the last 2 years or active cancer (other than plasma cell disorder)

Contacts and Locations

Study Contact

Laura Hawkins

CONTACT

507-538-1308

hawkins.laura@mayo.edu

Sarah Aug

CONTACT

507538-1301

aug.sarah@mayo.edu

Principal Investigator

Angela Dispenzieri, M.D.

PRINCIPAL_INVESTIGATOR

Mayo Clinic in Rochester

Study Locations (Sites)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

United States

Collaborators and Investigators

Sponsor: Mayo Clinic

Angela Dispenzieri, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic in Rochester

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-12-29

Study Completion Date2028-12-29

Study Record Updates

Study Start Date2021-12-29

Study Completion Date2028-12-29

Terms related to this study

Additional Relevant MeSH Terms

Plasma Cell Disorders